The radiolabelled material according to any preceding claim, wherein the metal-chelating agent is selected from the group consisting of ethylene diamine tetraacetic acid (EDTA), 1,4,7,10-tetraazacyclododecane-1,4,7,10-N,N′,N″,N′″-tetraacetic acid (DOTA), diethylene triamine pentaacetic acid (DTPA), mercaptoacetyltriglycine (MAG3), 6-Hydrazinopridine-3-carboxylic acid (Hynic), dimercaptosuccinic acid (DMSA), ethylene glycol-bis(β-aminoethyl ether)-N,N,N′,N′-tetraacetic acid (EGTA), triethylenetetramine (TETA), 1,4,7,10-tetraazacyclotridecane-1,4,7,10-N,N′,N″,N′″-tetraacetic acid (TRITA), 1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA), deferoxamine (desferral), sarcophagine (SarAr), 1,4,7,10-tetraazacyclododecane-1,4,7,10-N,N′,N″,N′″-tetra(methylene) phosphonic acid (DOTMP);
- 1,4,7,10-tetraazacyclotridecane-1,4,7,10-N,N′,N″,N′″-tetra(methylene)phosphonic acid;
- 1,4,7,10-tetraazacyclotetradecane-1,4,7,10-N,N′,N″,N′″-tetra(methylene) phosphonic acid;
- diethylene triamine-N,N′,N″-pentaacetic acid and isomeric derivatives thereof;
- cryptate[2,2,2], cryptate[3,2,2], cryptate[2,2,1] and mono and di-benzo derivatives thereof;
- bridged calix[4]arenes containing electron rich (donor) groups (hydroxyl, carboxyl, ester, amid, amine);
- 1,10-diaza-4,7,13,16-tetraoxacyclooctadecane-1,10-N,N′-bis-acetic acid;
- and 1,10-diaza-4,7,13, 16 tetraoxacyclooctadecane-1,10-N,N′-bis-malonate.